Notably, the combination of USP52 depletion and IKE administration dramatically inhibited tumor growth without any detectable side effects on the mice, as evidenced by no significant changes in mouse weight observed across the four groups (Figure 7B–E). Here, PAN2 is linked to neoplasm.